Where it comes from
- Made in
- Vasopressin neurons of the hypothalamus and the posterior pituitary, with vasopressin itself
- Sent out by
- With vasopressin
- Acts on
- Vasopressin neurons
What it does
In medicine
- No medicine copies it or blocks it, and it is not measured in people
- Vasopressin itself has medicines on both sides, agonists and the vaptan blockers; NERP-1 has neither, and no receptor for it has been found 3
Beyond the body’s own use
- Nothing containing it is in trials, approved or obtainable outside the laboratory
- Its interest is the arrangement rather than the molecule: the neurons that release vasopressin also release a peptide that holds vasopressin back, and both come from one precursor, so the brake is built into the signal 1
- What distinguishes it from NERP-2, cut from the same precursor, is that it does only this. NERP-2 restrains vasopressin as well, but also drives feeding through the orexin neurons, which NERP-1 does not 3
Sources
- Yamaguchi et al., Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and -2, Journal of Biological Chemistry 2007
- Toshinai et al., NERPs inhibit the excitability of magnocellular neurosecretory cells in the hypothalamus, Brain Research 2014
- Toshinai & Nakazato, Neuroendocrine regulatory peptide-1 and -2, bioactive peptides processed from VGF, Cellular and Molecular Life Sciences 2009
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.